N-(3-Formylquinolin-7-yl)acetamide | 363135-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(3-Formylquinolin-7-yl)acetamide
• 英文别名: 7-acetylamino-3-formylquinoline；N-(3-(formyl)-7-quinolinyl)acetamide
• CAS: 363135-51-7
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: WKOACUPLDNIAMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  59.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-Formylquinolin-7-yl)acetamide 在 盐酸 、 sodium tetrahydroborate 、 氯化亚砜 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 8.0h， 生成 3-(1-pyrrolidinylmethyl)-7-quinolinylamine hydrochloride
  参考文献：
  名称：

  Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl)quinolines

  摘要：

  It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.

  DOI：

  10.1021/jm201596h
• 作为产物：
  描述：

  间氨基乙酰苯胺 在 盐酸 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.0h， 生成 N-(3-Formylquinolin-7-yl)acetamide
  参考文献：
  名称：

  取代喹啉的高效合成

  摘要：

  将取代的苯胺加到 "乙脒 "双四氟硼酸盐 1 [2-二甲基氨基亚甲基-1,3-双（二甲基亚氨 基）丙烷双四氟硼酸盐]中，然后将生成的亚氨基烯胺盐环化，并水解被掩蔽的醛 2，从而得到相应的 3-甲酰基喹啉 3。虽然已知 1 及其类似的双高氯酸盐与脒的缩合可生成嘧啶，但我们认为这是第一个用 "乙烯脒 "双四氟硼酸盐 1 和苯胺进行喹啉环化反应的实例。

  DOI：

  10.1055/s-2001-15221

文献信息

• Quinoline compound
  申请人：Ishihara Yuji

  公开号：US20050209213A1

  公开（公告）日：2005-09-22

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Ar is a cyclic group optionally having substituent(s); X is a bond or a spacer having a main chain of 1 to 6 atoms; R 1 and R 2 are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R 1 and R 2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Y is a divalent hydrocarbon group optionally having substituent(s) (except CO); R 3 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring B may further have substituents, and when ring B further has a substituent, the substituent may be linked to R 1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有黑色素浓缩激素拮抗作用，可用作预防或治疗肥胖症的药物，其化学式为：其中，Ar是一个环状基团，可以有取代基；X是1到6个原子的主链的键或空隙；R1和R2相同或不同，分别是氢原子或烃基，可以有取代基，或者R1和R2可以与相邻的氮原子一起形成含氮杂环，可以有取代基；Y是一个双价的烃基，可以有取代基（除CO）；R3是氢原子或烃基，可以有取代基；环A和环B还可以有取代基，当环B还有取代基时，取代基可以与R1连接形成一个环，或其盐，或其前药。
• Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same
  申请人：Yamano Mitsuhisa

  公开号：US08373007B2

  公开（公告）日：2013-02-12

  Disclosed is a vinamidinium salt represented by the formula (I): [wherein R1 represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or the like; R2 and R3 are the same or different and each represents a lower alkyl group, or alternatively R2 and R3 may combine together to form a ring; R4 and R5 are the same or different and each represents a lower alkyl group, or alternatively R4 and R5 may combine together to form a ring; X and Y are the same or different and each represents a bromine atom or a chlorine atom; n represents a number of not less than 2; and m represents 0 or n], and methods for synthesizing a heterocyclic ring compound using the salt.

  本发明公开了一种由式(I)表示的维那米啶盐：[其中，R1表示氢原子、卤素原子、可选取代的碳氢基团或类似物；R2和R3相同或不同，分别表示较低的烷基基团，或者R2和R3可以结合形成一个环；R4和R5相同或不同，分别表示较低的烷基基团，或者R4和R5可以结合形成一个环；X和Y相同或不同，分别表示溴原子或氯原子；n表示不少于2的数字；m表示0或n]，以及使用该盐合成杂环环化合物的方法。
• QUINOLINE COMPOUND
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1447402A1

  公开（公告）日：2004-08-18

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula:    wherein Aris a cyclic group optionally having substituent(s) ; Xis a bond or a spacer having a main chain of 1 to 6 atoms; R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Yis a divalent hydrocarbon group optionally having substituent(s) (except CO); R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有拮抗黑色素浓缩激素的作用，可作为预防或治疗肥胖症的药物，由式表示： 式中 Ar 是一个环状基团，可选择具有取代基； X 是主链为 1 至 6 个原子的键或间隔物； R1 和 R2 相同或不同，各自为氢原子或任选具有取代基的烃基，或 R1 和 R2 可与邻近的氮原子一起形成任选具有取代基的含氮杂环； Y 是可选具有取代基的二价烃基（CO 除外）； R3 是氢原子或可选具有取代基的烃基；以及 环 A 和环 B 可进一步具有取代基，当环 B 进一步具有取代基时，该取代基可与 R1 连接形成一个环、 或其盐或其原药。
• EP1447402
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of a stable triformylmethane synthon and its scalable application to 7-acylamino-3-formylquinoline syntheses
  作者：Yasuhiro Sawai、Masahiro Mizuno、Tatsuya Ito、Mitsuhisa Yamano

  DOI：10.1016/j.tet.2014.02.040

  日期：2014.4

  Novel 2-iminiomethylvinamidinium trihalides were isolated as stable crystals and found to be useful triformylmethane synthons with non-deliquescent nature in air. They were easier to manufacture, handle, and store than the known 2-iminiomethylvinamidinium dichloride. By virtue of in situ aminal protection, a combination of the vinamidinium salt with a secondary amine achieved an efficient and scalable synthesis of 7-acylamino-3-formylquinoline, a versatile synthetic intermediate for potent anti-obesity drugs 7-acylamino-3-aminomethy1-8-methylquinolines. (C) 2014 Elsevier Ltd. All rights reserved.